Targeting the Dimerization of the Main Protease of Coronaviruses: A Potential Broad-Spectrum Therapeutic Strategy.
Antiviral Agents
/ pharmacology
Betacoronavirus
/ chemistry
COVID-19
Coronavirus 3C Proteases
Coronavirus Infections
/ drug therapy
Cysteine Endopeptidases
/ chemistry
Drug Discovery
Humans
Models, Molecular
Molecular Targeted Therapy
Mutation
/ drug effects
Pandemics
Peptides
/ pharmacology
Pneumonia, Viral
/ drug therapy
Protease Inhibitors
/ pharmacology
Protein Conformation
/ drug effects
Protein Multimerization
/ drug effects
SARS-CoV-2
Viral Nonstructural Proteins
/ antagonists & inhibitors
3CLpro
COVID-19
SARS-CoV
SARS-CoV-2
broad-spectrum antiviral agents
coronavirus
dimerization
homodimer
main protease (Mpro)
mutation
Journal
ACS combinatorial science
ISSN: 2156-8944
Titre abrégé: ACS Comb Sci
Pays: United States
ID NLM: 101540531
Informations de publication
Date de publication:
08 06 2020
08 06 2020
Historique:
pubmed:
14
5
2020
medline:
17
6
2020
entrez:
14
5
2020
Statut:
ppublish
Résumé
A new coronavirus (CoV) caused a pandemic named COVID-19, which has become a global health care emergency in the present time. The virus is referred to as SARS-CoV-2 (severe acute respiratory syndrome-coronavirus-2) and has a genome similar (∼82%) to that of the previously known SARS-CoV (SARS coronavirus). An attractive therapeutic target for CoVs is the main protease (M
Identifiants
pubmed: 32402186
doi: 10.1021/acscombsci.0c00058
doi:
Substances chimiques
Antiviral Agents
0
Peptides
0
Protease Inhibitors
0
Viral Nonstructural Proteins
0
Cysteine Endopeptidases
EC 3.4.22.-
Coronavirus 3C Proteases
EC 3.4.22.28
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM